Texas Yale Capital Corp’s Avidity Biosciences RNAM Stock Holding History

Texas Yale Capital Corp’s Portfolio RNAM Stock Details RNAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-10,000	Closed	-$255K	–	454
2024 Q1	$255K	Hold	10,000	–	–	0.01%	399
2023 Q4	$90.5K	Hold	10,000	–	–	﹤0.01%	420
2023 Q3	$63.8K	Hold	10,000	–	–	﹤0.01%	410
2023 Q2	$111K	Hold	10,000	–	–	0.01%	425
2023 Q1	$154K	Hold	10,000	–	–	0.01%	431
2022 Q4	$222K	Hold	10,000	–	–	0.01%	416
2022 Q3	$163K	Hold	10,000	–	–	0.01%	424
2022 Q2	$145K	Hold	10,000	–	–	0.01%	423
2022 Q1	$185K	Hold	10,000	–	–	0.01%	437
2021 Q4	$238K	Hold	10,000	–	–	0.01%	406
2021 Q3	$246K	Hold	10,000	–	–	0.01%	399
2021 Q2	$247K	Hold	10,000	–	–	0.01%	401
2021 Q1	$218K	Buy	+10,000	New	+$245K	0.01%	414

Other funds holding RNAM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Texas Yale Capital Corp's RNAM Position: Q2 2024 in Review

Texas Yale Capital Corp sold out of Avidity Biosciences (RNAM) in Q2 2024, closing a stake of 10,000 shares — an estimated $255K sold.

Texas Yale Capital Corp first reported a position in RNAM in Q1 2021 and held it in 13 quarters. The position peaked at $255K in Q1 2024. 196 funds tracked by Wall St. Rank hold RNAM as of Q2 2024.

Texas Yale Capital Corp reported no remaining Avidity Biosciences position as of Q2 2024 after selling out during the quarter.
Texas Yale Capital Corp sold 10,000 Avidity Biosciences shares in Q2 2024, an estimated $255K.
Texas Yale Capital Corp first reported a position in Avidity Biosciences in Q1 2021 and held it in 13 quarters.
Texas Yale Capital Corp's Avidity Biosciences position peaked at $255K in Q1 2024.
196 funds tracked by Wall St. Rank held Avidity Biosciences as of Q2 2024.

Based on Texas Yale Capital Corp's 13F filing for Q2 2024, filed 13 Aug 2024.